Otsuka Precision Health, a prescription digital therapeutics company, and Amalgam Rx, a holdings company in the pharmaceutical and nutraceutical market, have launched Elevmi, a digital application designed to help caregivers assist family members who have been diagnosed with Alzheimer's Disease. 

Elevmi helps caregivers access information and get support by "leveraging AI's power to deliver curated, personalized context."

The aim of Elevmi is to make it easy for caregivers to manage their loved ones by enabling them to understand their condition over time while also supporting the caregivers’ mental health and wellness. 

With the use of Elevmi’s conversational AI, caregivers can participate in a dialogue regarding their experiences and have the ability to ask questions about the patient's condition.

Elevmi’s user experience is managed by a large language model trained on content from the National Institute on Aging (NIA) that is part of the National Institutes of Health (NIH) and PsychU.

"At OPH, we are committed to developing and scaling individualized solutions for the whole person that improve quality of life," Sanket Shah, president of OPH, said in a statement.

"We realize that caregivers play a critical role in supporting patients with Alzheimer's and in addition to working on patients focused solutions, we wanted to bring Elevmi to stay true to our mission in supporting the whole person's care. We hope to reduce the stress and burden caregivers experience by enhancing their ability to manage and coordinate care for the people that rely on them while directly supporting improvements in their quality of life."

Ryan Sysko, chief executive officer of Amalgam Rx, said that the company has been developing medical-grade generative AI for years. 

"Our AI platform has been purpose-built with appropriate guardrails for life sciences and other healthcare companies. Our collaboration with OPH is a great example of working with our customers to navigate the complexities and responsibly bring real innovation to patients and caregivers."

THE LARGER TREND

In 2022, Jolly Good and Otsuka Pharmaceutical, the parent company of Otsuka Precision Health, inked an exclusive product development and sales deal designed to expand the use of social skill training VR in treating mental disorders in Japan. 

The five-billion-yen ($43.7 million) deal will have Jolly Good delivering VR goggles, tablet devices and SST VR content to expand the use of social skill training VR in treating mental disorders in Japan.

A year before, Otsuka Pharmaceutical and Click Therapeutics launched a fully remote clinical trial conducted on Verily's Project Baseline platform. The Mirai study measured a digital therapeutics intervention's effectiveness in lowering symptoms of depression in adults with a major depressive disorder (MDD) diagnosis and are taking antidepressant monotherapy agents.

In 2021, Amalgam acquired the assets of Geetha, a company that developed AI models that can discover patients and health stakeholder's behavior, and then deliver behavior-change content. Amalgam Rx gained the company's "psychosocial engine" which can use data and AI to gain insights into the personality, moods and motivators of people in 40 languages. 

In 2021, Amalgam Rx acquired clinical-decision-support company Avhana Health. The acquisition represented a new service for Amalgam Rx, that spanned multiple facets of digital health, such as patient support programs, digital therapies and combination products. Avhana’s platform integrates into doctor’s workflows and makes suggestions regarding patient care, like what to add to orders.